CAPROCK Group Inc. purchased a new position in Heska Corporation (NASDAQ:HSKA) during the second quarter, Holdings Channel reports. The fund purchased 1,975 shares of the medical research company’s stock, valued at approximately $202,000.

A number of other large investors also recently bought and sold shares of HSKA. Neuberger Berman Group LLC boosted its stake in Heska Corporation by 60.8% in the first quarter. Neuberger Berman Group LLC now owns 445,245 shares of the medical research company’s stock worth $46,742,000 after buying an additional 168,293 shares during the last quarter. Vanguard Group Inc. boosted its stake in Heska Corporation by 47.0% in the first quarter. Vanguard Group Inc. now owns 350,609 shares of the medical research company’s stock worth $36,807,000 after buying an additional 112,115 shares during the last quarter. Riverbridge Partners LLC boosted its stake in Heska Corporation by 257.0% in the first quarter. Riverbridge Partners LLC now owns 244,031 shares of the medical research company’s stock worth $25,618,000 after buying an additional 175,674 shares during the last quarter. Russell Investments Group Ltd. boosted its stake in Heska Corporation by 18.1% in the second quarter. Russell Investments Group Ltd. now owns 225,388 shares of the medical research company’s stock worth $23,005,000 after buying an additional 34,594 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in Heska Corporation by 29.6% in the first quarter. Bank of New York Mellon Corp now owns 202,552 shares of the medical research company’s stock worth $21,264,000 after buying an additional 46,231 shares during the last quarter. Institutional investors and hedge funds own 81.48% of the company’s stock.

Heska Corporation (NASDAQ HSKA) opened at 100.39 on Tuesday. The firm has a market capitalization of $709.56 million, a PE ratio of 51.17 and a beta of 0.82. The stock’s 50 day moving average is $100.69 and its 200-day moving average is $95.04. Heska Corporation has a one year low of $43.72 and a one year high of $115.00.

Heska Corporation (NASDAQ:HSKA) last issued its quarterly earnings results on Thursday, August 3rd. The medical research company reported $0.44 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.37 by $0.07. The company had revenue of $34.30 million during the quarter, compared to analyst estimates of $33.35 million. Heska Corporation had a net margin of 10.70% and a return on equity of 15.87%. Heska Corporation’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same period last year, the business earned $0.35 EPS. On average, analysts anticipate that Heska Corporation will post $2.04 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This report was first reported by Daily Political and is the sole property of of Daily Political. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.dailypolitical.com/2017/08/08/caprock-group-inc-purchases-shares-of-1975-heska-corporation-hska.html.

HSKA has been the subject of a number of research reports. Aegis raised their price target on shares of Heska Corporation from $114.50 to $129.50 and gave the stock a “buy” rating in a report on Tuesday, August 1st. B. Riley restated a “neutral” rating and issued a $85.00 price target on shares of Heska Corporation in a report on Monday, May 8th. BidaskClub cut shares of Heska Corporation from a “buy” rating to a “hold” rating in a report on Sunday, July 16th. Finally, Zacks Investment Research upgraded shares of Heska Corporation from a “hold” rating to a “buy” rating and set a $109.00 price target for the company in a report on Friday. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $105.20.

In related news, COO Jason A. Napolitano sold 5,000 shares of the stock in a transaction dated Wednesday, May 24th. The shares were sold at an average price of $100.50, for a total value of $502,500.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Carol Wrenn sold 1,630 shares of the stock in a transaction dated Tuesday, May 23rd. The stock was sold at an average price of $96.95, for a total transaction of $158,028.50. Following the completion of the transaction, the director now owns 6,174 shares of the company’s stock, valued at $598,569.30. The disclosure for this sale can be found here. Over the last quarter, insiders sold 30,265 shares of company stock valued at $2,983,439. 14.70% of the stock is owned by company insiders.

Heska Corporation Company Profile

Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.

Want to see what other hedge funds are holding HSKA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heska Corporation (NASDAQ:HSKA).

Institutional Ownership by Quarter for Heska Corporation (NASDAQ:HSKA)

Receive News & Ratings for Heska Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska Corporation and related companies with MarketBeat.com's FREE daily email newsletter.